Survival rates for multiple myeloma vary by the stage at which it’s diagnosed. Overall, the five-year survival rate is 58% according to the American Society of Clinical Oncology.

GlaxoSmithKline (GSK) is conducting a Phase 3 study titled A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and ...

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

The first sign of multiple myeloma varies by person and may not occur until a later stage of the disease. Learn how to ...

For patients unable to withstand the increased toxicity of a four-drug regimen, the two most commonly used triplet regimens ...

Patients have been asking me about a recently published article that suggests a "'potential cure"' for myeloma is at hand.

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

Despite decades of research, multiple myeloma remains an incurable disease. A wide array of therapies, such as proteasome ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial ...

The discussion focused on the diagnostic process for multiple myeloma, emphasizing the importance of comprehensive evaluation through various clinical tools. Diagnosing this complex disease requires ...

Multiple myeloma has an incidence of approximately 4-5 new cases per 100,000 inhabitants per year. This means that around 3000 new cases are diagnosed each year in Spain.